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Preeclampsia is a syndrome characterized by hypertension during pregnancy, which is
a leading cause of morbidity and mortality in both mother and newborn in developing
countries. Some advances have increased the understanding of pathophysiology of
this disease. For example, reduced utero-placental blood flow associated with impaired
trophoblast invasion may lead to a hypoxic placenta that releases harmful materials into
the maternal and feto-placental circulation and impairs endothelial function. Identification
of these harmful materials is one of the hot topics in the literature, since these
provide potential biomarkers. Certainty, such knowledge will help us to understand
the miscommunication between mother and fetus. In this review we highlight how
placental extracellular vesicles and their cargo, such as small RNAs (i.e., microRNAs),
might be involved in endothelial dysfunction, and then in the angiogenesis process,
during preeclampsia. Currently only a few reports have addressed the potential role of
endothelial regulatory miRNA in the impaired angiogenesis in preeclampsia. One of the
main limitations in this area is the variability of the analyses performed in the current
literature. This includes variability in the size of the particles analyzed, and broad variation
in the exosomes considered. The quantity of microRNA targets genes suggest that
practically all endothelial cell metabolic functions might be impaired. More studies are
required to investigate mechanisms underlying miRNA released from placenta upon
endothelial function involved in the angiogenenic process.
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INTRODUCTION
Preeclampsia is a syndrome diagnosed with hypertension and concomitant multisystemic
dysfunction during pregnancy. Epidemiological and socio-economic studies highlight the relevance
of preeclampsia worldwide. However, despite the fact that the pathophysiology of preeclampsia
is not entirely understood; there is no doubt that endothelial dysfunction in both maternal and
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feto-placental circulation is one of the hallmarks in this disease.
In this review we propose to highlight new biomarkers, such as
extracellular vesicles and small RNAs (i.e., microRNAs) involved
in endothelial dysfunction during preeclampsia. Since, abundant
information is available in the current literature on this topic, we
will restrict our analysis to information regarding angiogenesis as
a target.
PREECLAMPSIA: GENERAL OVERVIEW
Preeclampsia is syndrome characterized by new onset
hypertension and proteinuria after 20 weeks of gestation
(Roberts and Hubel, 2009). However, the American College
of Obstetricians and Gynecologists has stated in their revised
guidelines that proteinuria is no longer absolutely required for
diagnosis of preeclampsia (ACOG TFoHiP, 2013). In the absence
of proteinuria, the diagnosis may be established by the presence
of hypertension associated with thrombocytopenia, impaired
liver functions, and the development of renal insufficiency,
pulmonary edema, or the onset cerebral or visual disturbances
previously not experienced.
Preeclampsia affects about 10% of all pregnancies worldwide
(Duley, 2009). Globally, it is the leading cause of maternal and
neonatal mortality. This imposes substantial burdens on the
families of pregnant women, their communities, and healthcare
systems (Duley, 2009). Each year, it is estimated that hypertension
during pregnancy, particularly preeclampsia, complicates 10
million pregnancies, resulting in 76,000 maternal mortality and
the loss of 500,000 fetal and/or newborns worldwide (Khowaja
et al., 2015). Nearly all of these maternal deaths (>99%) occur
in low-and middle-income countries (Duley, 2009). In addition,
preeclampsia is a risk factor for cardiovascular disease for both
mother and child later in life (Agatisa et al., 2004; Mongraw-
Chaffin et al., 2010; Davis et al., 2012a). Women who have had
preeclampsia exhibit at least a two-fold increased risk of stroke,
while risk of death due to ischemic heart disease is eight times
higher when preeclampsia occurs before 34 weeks of gestation
(Mongraw-Chaffin et al., 2010). Indeed, the American Heart
Association (AHA) has included preeclampsia as a risk factor for
future cardiovascular disease (CVD) with the recommendation
to obtain a history of preeclampsia and to improve lifestyle
behaviors of womenwith such a history (Agatisa et al., 2004; Seely
et al., 2013).
Preeclampsia is also a major cause of infant morbidity and
mortality worldwide (Xiong et al., 2002; Duley, 2009). Stillbirth
is more common in preeclamptic pregnancies while one third
of infants of preeclamptic women are growth restricted (Sibai
et al., 2005; Villar et al., 2006) and preterm delivery is twice
as common in preeclampsia as in normotensive pregnancies
(Villar et al., 2006). Furthermore, numerous epidemiological and
experimental studies suggest an important role for an adverse
intrauterine environment in the development of chronic disease
in adult life (Hanson and Gluckman, 2008; Glover, 2011; Davis
et al., 2012b). Applying this concept to preeclampsia, many
epidemiological studies (Kajantie et al., 2009; Wu et al., 2009,
2011; Davis et al., 2012a,b; Lawlor et al., 2012) indicate that
preeclampsia is associated with long-term adverse outcomes in
the offspring. The majority of studies report that children and
adolescents who were exposed to preeclampsia or hypertension
in pregnancy exhibit higher systolic and diastolic blood pressure
compared with non-exposed children or adolescents (see details
in Davis et al., 2012a). In addition, Kajantie et al. (2009)
reported that the risk for stroke in subjects born from
preeclamptic pregnancies was twice that of controls born from
normotensive pregnancies. Other studies have described an
increased risk for pulmonary hypertension (Jayet et al., 2010),
metabolic and endocrine disease (Wu et al., 2009, 2011),
depression (Tuovinen et al., 2010), cerebral palsy (Szymonowicz
and Yu, 1987), poor cognitive outcome (Cheng et al., 2004),
or intellectual disabilities (Griffith et al., 2011) in children
born of preeclamptic pregnancies compared to non-exposed
children.
PATHOPHYSIOLOGY OF PREECLAMPSIA
Preeclampsia is characterized by impaired cytotrophoblast
transformation toward extravillous trophoblasts that result in
reduced invasion into the maternal vascular bed (Burton et al.,
2009a,b). This phenomenon leads to reduced trophoblastic
invasion into maternal spiral vessels preventing their
transformation into capacitance vessels. This in turn impairs
maternal blood flow to the placenta and also results in high
perfusion pressure in the intervillus space generating shear stress
to the trophoblast (Burton et al., 2009b). This stress, damages
trophoblast leading to detachment and release of cell fragments,
microparticles, and extracellular vesicles (EVs; including a
wide range of size, see below) into the maternal circulation
(Tannetta et al., 2013). Within these EVs harmful elements
can be transported into maternal circulation causing maternal
endothelial dysfunction. At the same time, these changes
generate a vicious cycle that also affects the placental blood flow
leading to further release of placental materials that adversely
affect maternal endothelial function (Roberts and Escudero,
2012). Not surprisingly, harmful molecules from the placenta can
also reach the fetal circulation causing endothelial dysfunction.
Indeed, many reports including some from our group (Wadsack
et al., 2012; Escudero et al., 2014a) have described feto-
placental endothelial dysfunction accompanying preeclamptic
pregnancies.
Amongst other harmful molecules released from the placenta,
the soluble vascular endothelial growth factor receptor type 1
(sFlt1) has received much attention in preeclampsia. However,
many other factors are also involved in the harmful signaling
causing endothelial dysfunction in the maternal circulation.
Some of the most recently identified elements are placental
exosomes, containing molecules such as microRNAs that can
incorporate into the maternal cells and modify the expression
of targets genes. Currently, study of EVs and microRNA in the
maternal circulation and/or in placentae from preeclampsia is
extensively studied (see for instance Chen and Wang, 2013; Fu
et al., 2013a), since potential predictive tools and mechanistic
insights can be obtained using microRNA-omic analysis.
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ENDOTHELIAL DYSFUNCTION IN
PREECLAMPSIA
Endothelial dysfunction is a systemic pathological state
characterized by an imbalance between vasodilator and
vasoconstrictor molecules produced by or acting on the
endothelium (Brunner et al., 2005; Deanfield et al., 2005). In
this regard, several publications have described endothelial
dysfunction in maternal (Rodgers et al., 1988; Roberts et al.,
1989; Roberts, 1998), and in the feto-placental circulation
during preeclamptic pregnancies (see details in Sobrevia et al.,
2012; Wadsack et al., 2012) or in children born to women with
preeclampsia (Jayet et al., 2010; Lazdam et al., 2010; Kvehaugen
et al., 2011; Davis et al., 2012b).
Amongst the many markers associated with impaired
endothelial function, we will highlight those related to
angiogenesis (Shibuya, 2006; Escudero et al., 2009) and
metabolic regulation of endothelium (Verdegem et al., 2014).
sFlt-1 is a decoy receptor for the vascular endothelial growth
factor (VEGF) which binds VEGF and placental growth factor
(PlGF) to prevent activation of VEGF receptor type 2 (VEGFR2)
in mothers (Parra et al., 2005; Chaiworapongsa et al., 2008,
2010, 2011; Kusanovic et al., 2009; Veas et al., 2011; Parra-
Cordero et al., 2013), and feto-placental tissues (Bosco et al.,
2012; Escudero et al., 2013, 2014b). High levels are present in
preeclamptic pregnancies. There is extensive evidence indicating
that VEGF/VEGFRs dysregulation is present in preeclampsia as
a hallmark of endothelial dysfunction in mothers and perhaps in
their children. Another indicator of endothelial dysfunction is
the impaired synthesis and bioavailability of nitric oxide (NO), a
vasodilator and angiogenic regulator. This is due in large part to
reduced expression and/or activation of endothelial nitric oxide
synthase (eNOS) and/or inactivation of NO by reactive oxygen
species associated with imbalance between oxidase activity and
antioxidant enzyme systems (Myatt and Webster, 2009) or
competitive inhibition by asymmetric dimethylarginine (ADMA;
Speer et al., 2008).
Another example of endothelial dysfunction in preeclampsia
is related to transport and catabolism of metabolic active
substrates, including glucose, amino acids, or fatty acids. This
is a relevant issue since most of the energy of endothelial cells
comes from glycolysis (Verdegem et al., 2014). In preeclampsia,
inactivation of glucose-6-phosphate dehydrogenase (G6PD), a
rate-limiting enzyme in glucose metabolism, occurs in the
fetal circulation, a phenomenon associated with the vascular
dysfunction and oxidative stress observed in this disease
(Afzal-Ahmed et al., 2007). Similarly, reduced transport and/or
metabolism of other bioactive molecules such as adenosine or
L-arginine (Casanello et al., 2007), ormetabolism of other sources
of energy such as fatty acids (Wadhwani et al., 2014), might
also contribute to the metabolic alterations leading to endothelial
dysfunction in preeclampsia.
It has been proposed that cell fragments observed in
maternal circulation during normal or pathological pregnancies
are mechanisms for signaling between the fetus and the
mother. Feto-maternal signaling may induce vascular and
cardiac adaptations during normal pregnancies, which could
be pathologically exaggerated during preeclampsia. At least two
mechanisms of signaling will be described in this manuscript that
are mediated by exosomes and microRNAs. Dozens of studies
have sought to decipher their role in signaling between fetus and
mother, or as biomarkers of preeclampsia. However, few have
studied the endothelial cell as a potential target for exosomes and
miRNAs released from the placenta.
EXTRACELLULAR VESICLES
Extracellular vesicles (EV) are lipid-bilayer structures that are
released from cells into the extracellular environment (Mitchell
et al., 2015). They contain proteins, miRNA, growth and
apoptotic factors, and other regulatory components to induce
cell-to-cell communication and signaling throughout the body
(Colombo et al., 2014). EVs are released under normal and
pathological conditions. It is apparent that multiple EV types
can be produced from different cells, including red blood
cells (Simpson et al., 2008), fibroblasts (Stadtman and Levine,
2000), endothelial cells (Winyard et al., 2011), and trophoblasts
(Salomon et al., 2013). After secretion from cells, the EVs may
modify the activity of adjacent cells or travel to regions distal
to the site of release in several bodily fluids (e.g., lymph, saliva,
blood, mammary glands secretions; Yanez-Mo et al., 2015). EVs
are distinguished by size, function, biogenesis (Cocucci et al.,
2009), and morphology (Mathivanan et al., 2010) into three
categories: microvesicles, apoptotic bodies, and exosomes. Please
review Mitchell et al. (2015).
Exosomes are the smallest of EVs, 40 to 120 nm. They are
characterized by their endosomal origin and formation through
the inward budding of multivesicular bodies (MVB; Kowal et al.,
2014). Their density ranges from 1.13 to 1.19 g/mL and they
are released into biofluid compartments via exocytosis (Kowal
et al., 2014). Exosomes are enriched with endosomal membrane
markers (e.g., CD9, CD63, TSG101, and CD81; Mitchell et al.,
2015).
Microvesicles, or microparticles, are larger than exosomes,
100–1000 nm in size (Akers et al., 2013). They are the products
of tumors (Whiteside, 2005), erythrocytes (Aatonen et al., 2014),
and platelets (Fourcade et al., 1995). They are classified as
ectosomes due to their derivation from the plasma membrane
(Heijnen et al., 1999) and their biogenesis has been shown to be
controlled by key proteins such as ARF6 (D’Souza-Schorey and
Chavrier, 2006), RhoA (Li et al., 2012), and Calpain (Crespin
et al., 2009). Microvesicles are enriched with CD40 protein
markers (Kowal et al., 2014).
Apoptotic bodies are formed by direct budding of cells
during apoptosis and are the largest EV, 1000–5000 nm in size
(Perez-Hernandez and Cortes, 2015). They also enriched with
histones and DNA (Kowal et al., 2014). Since the size range
of the several vesicles overlap, isolation, and characterization
remains a challenge in EV research. Nonetheless, EV content
is cell-specific and has distinct functions directed at specific
cells (Mathivanan and Simpson, 2009). No universal EV
isolation technique has been established and consequently
many strategies are used for the separation of these vesicles.
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These include differential density ultracentrifugation, exosome
growth enrichment, immunoaffinity beads directed toward
surface proteins, and size-exclusion chromatography. Despite
that, characterization of size, cargo, and function of EVs and
particularly exosomes is one of the cutting-edge topics in
preeclampsia (Mitchell et al., 2015).
In addition, the release of EVs is dependent on their
microenvironment, influenced by factors such as oxygen tension
or glucose concentrations. Glucose regulates intracellular Ca2+
concentration, and via this mechanism may alter the rate
of exocytosis. At high D-glucose concentrations, release of
exosomes from trophoblast cells is increased (Rice et al.,
2015) either by an increased rate of exocytosis, the migration
of multivesicular bodies (MVBs) to the plasma membrane,
increased EV production withinMVBs, or a combination of these
factors (Savina et al., 2003; MacDonald et al., 2005; Dai et al.,
2011). Oxygen concentration also plays a key role in EV release
and content regulation.
Incorporation of EVs into recipient cells, and in particular
into endothelial cells, involves toll like receptor (TIR) signaling.
Thus, endothelial cells incubated with EVs derived from
endothelium that have been stimulated by anti-β2 glycoprotein,
a phospholipid-binding protein linked with endothelial
dysfunction and present in the anti-phospholipid syndrome,
exhibited increased phosphorylation of IRAK4, a downstream
protein in the TIR signaling pathway (Wu et al., 2015). In other
experiments IRAK siRNA inhibited EV-induced endothelium
activation, as measured by increased E-selectin cell surface
expression. In order to determine which toll like receptor
(TLR) may be involved in this phenomenon, investigators used
siRNAs for TLR2, TLR4, TLR7, and TLR9. Only treatment with
TLR7 and TLR9, blocked EV-induced endothelium activation.
TLR9 siRNA also decreased expression of TLR7, suggesting
TLR7 as the main regulator of EVs effect on endothelial cells.
Since TLR7 is activated in response to ssRNA and miRNAs,
authors performed experiments in presence of RNase A, which
also inhibited activation of endothelial cells. Finally, EVs from
endothelium stimulated by anti-β2 glycoprotein had at least
12 miRNAs upregulated and six downregulated compared to
unstimulated control cells. miR126, was identified as targeting
endothelium. These results indicate a paracrine pathway for
EVs-mediated activation of endothelial cells, with selective
incorporation of EVs into target cells directed by TLR7.
EXTRACELLULAR VESICLE FUNCTION IN
PREGNANCY
The concentration of placentally derived exosomes in maternal
plasma increases progressively (see Figure 1; Sarker et al.,
2014). It has been suggested that EVs may be active mediators
that communicate between the maternal endometrium and
the embryo (Ng et al., 2013) at the time of implantation
regulating endometrial remodeling. They are also proposed to
regulate physiological adaptation throughout pregnancy (Ng
et al., 2013; Sarker et al., 2014), including the modification
of maternal immune cell responses and syncitiotrophoblast
function locally and systemically. For example, under hypoxic
conditions during early pregnancy, cytotrophoblast cells and
placental mesenchymal stem cells are stimulated to increase
EV release, accompanied by changes in vesicle contents and
bioactivity (Salomon et al., 2013).
EVs have also been linked to spiral artery (SpA) remodeling,
an adaptation necessary to provide sufficient gas and nutrient
exchange from the maternal to fetal side of the placenta (Harris,
2011). The result of normal SpA remodeling is the formation of
maternal arteries that are dilated and with reduced resistance to
flow of blood from mother to the intervillus space (Cockell and
Poston, 1997). This remodeling is associated with extravillous
EV signaling and is proposed to stimulate endothelial cell
migration resulting in vascular tube formation (ZhangH. C. et al.,
2012). Interestingly, placental-derived exosomes carry syncytin
proteins, which contribute to fusion of cytotrophoblast cells
to form syncytiotrophoblast cells, which in turn constitute the
maternal-placental interface (Record, 2014; Vargas et al., 2014).
Extracellular vesicles may also induce release of
proinflammatory cytokines (Atay et al., 2011). The interaction
between EV proteins and peripheral blood mononuclear cells
or dendritic cells can initiate stem cell differentiation. This
promotes increased cell migration and suppresses the activation
of natural killer cells and macrophages altering inflammatory
response during pregnancy (Mincheva-Nilsson et al., 2006;
Knight, 2008). Exosomes secreted from placenta contain specific
proteins and act upon target immune cells to provide an
immunosuppressive environment during pregnancy. Proteins
isolated from trophoblast cells suppress maternal immune
system, which is essential for fetal semiallograft survival. MHC
class I related molecules (Mincheva-Nilsson et al., 2006), down
regulated Natural killer cell receptor (NKG2D; Hedlund et al.,
2009), functional Fas ligand (Frangsmyr et al., 2005), and TRAIL
molecules, the HLA-G and B7 family of immunomodulators
(Kshirsagar et al., 2012) isolated from first trimester placental
tissues suppressed T cell signaling components.
EXTRACELLULAR VESICLES IN
PREECLAMPSIA
In preeclampsia, impaired placental function with placental
apoptosis and necrosis causes increased release of microvesicles
and nanovesicles (i.e., exosomes; see Figure 2). These exosomes
contain proteins, miRNA, DNA, RNA; as well the lipids
comprising the vesicular wall. These components are involved in
several stages of the pathogenesis of preeclampsia. Extracellular
vesicles (including exosomes) originating from placental
explant and placental cells promote pro-inflammatory cytokines
production (Germain et al., 2007) and endothelial dysfunction
(Cockell et al., 1997).
Using a placental marker (i.e., Placental Alkaline Phosphatase,
PLAP), placenta-derived vesicles were identified in maternal
plasma as early as the first trimester of pregnancy (Cockell et al.,
1997). The immunoreactive exosomal PLAP was not detectable
in plasma of non-pregnant women (Sabapatha et al., 2006;
Dragovic et al., 2013; Salomon et al., 2014a). The role of placental
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FIGURE 1 | Extracellular vesicles released from placenta in normal pregnancy. Extracellular vesicles (EVs) include exosomes, microvesicles, and
apoptotic bodies all with different size and origin. With adequate blood flow from the mother to the placenta resulting in normal oxygen tension and glucose
(nutrient) concentration, a limited number of EVs are shed from the placenta into the maternal circulation. Cargo and function of the EVs are not completely
understood. However, they may constitute a common language between feto-placental tissue and mother with interchange of information leading to normal
blood flow supply (from the mother to the placenta). Feto-placental extracellular vesicles may also modulate maternal endothelial cell function. The cargo of
exosomes, of endosomal origin, including proteins and nucleic acids, such as microRNAs may be “planned” by the placenta. This cargo controls endothelial
cell protein expression leading modifying multiple pathways including among others metabolic and survival-death signals. Appropriate communication allows
successful pregnancy and fetal development.
exosomal bioactivity (i.e., release, content and interaction with
target cells) under normal or pathological conditions (e.g., PE)
has not been fully established (Mitchell et al., 2015). Nonetheless,
some models have been used to address this issue. For instance,
with hypoxia, the number of extracellular vesicles released
from several cell types are modified (Salomon et al., 2013).
At lower oxygen concentrations, the amount of functional EVs
increases leading to a spike in EVT migration. The content
of the EVs are also changed, which may cause endothelial
cell dysfunction and direct placentation toward abnormal SpA
remodeling.
Specific protein and lipids of EVs produced by
syncytiotrophoblasts are altered in preeclampsia (Redman
and Sargent, 2008). For instance, among 400 proteins identified
within syncytiotrophoblast-derived EVs, at least 25 of these
were unique to preeclamptic pregnancies, including integrins,
annexins, and histones (Baig et al., 2014). In another study
(Vargas et al., 2014) the specific syncytiotrophoblast protein,
syncytin-2, was markedly down-regulated in exosomes from
placentas of pregnant women with preeclampsia compared
to normal pregnancies. In addition, the EV lipid profile in
human placental syncytiotrophoblast microvesicles derived from
preeclamptic pregnancies identified ∼200 distinct lipids. These
included a higher concentration of phosphatidylserine and a
lower concentration of phosphatidic acid, ganglioside mannoside
3, and phosphatidulglycerol (Baig et al., 2013).
MicroRNAs are also present within exosomes (see section
below). Placental specific miRNA molecules were identified
within placental exosomes (Ouyang et al., 2014) that were
resistant to viral infection apparently to protect the fetus during
pregnancy (Bullerdiek et al., 2013; Delorme-Axford et al., 2013;
Mouillet et al., 2014). Exosomes are released in low concentration
during normal pregnancy but release from syncitiotrophoblast
is increased in endothelial and immune-cell dysfunction as is
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FIGURE 2 | Exosomes released from the placenta: focus on preeclampsia. As in normal pregnancy extracellular vesicles (EVs) include exosomes,
microvesicles, and apoptotic bodies all with different size and origin are present. However, abnormal placentation secondary to reduced trophoblast invasion and
failed remodeling of spiral arteries leads to reduced oxygen tension, impaired nutrient transport and exposure to increased shear stress for the syncitiotrophoblast.
Under these stressful conditions more EVs are shed from the placenta into the maternal circulation. Messages carried by in the EVs are not completely understood;
however, it is proposed that they cause endothelial dysfunction with associated elevation of maternal blood pressure. This figure indicates some of miscommunication
generated by the placenta via exosomes and its cargo, microRNAs. Potential effects upon maternal endothelial cells by the family of miR-126, miR-17, miR-18,
miR-19, miR-92, and miR-210 are detailed in the manuscript. In preeclampsia multiple pathways may be impaired including metabolic and death signaling by this
microRNAs among others.
associated with the placental pathophysiology in preeclampsia
(Pant et al., 2012).
In view of this evidence, it is hypothesized that the effect of
these nanovesicles is determined by the cellular origin and/or
exosomal content (e.g., proteins, miRNA, DNA, RNA, lipids,
etc.). These are proposed to direct placental function in early
normal pregnancy but also to be potentially important to
disorder placentation in complicated pregnancies (Salomon et al.,
2014a) providing a potential biomarker for preeclampsia (see
Table 1).
OVERVIEW OF microRNA
Micro-RNAs (miRNAs, 21–25 nucleotides) are critical regulators
of gene expression. Canonically, miRNAs are transcribed by
RNA polymerase II from individual miRNA genes, intron
of protein coding genes, or polycistronic transcripts such
as capped and polyadenylated primary miRNA transcripts
(pri-miRNA, ∼70 nucleotides). Several nuclear and cytoplasmic
enzymes process pri-miRNAs, and miRNA are finally processed
to 22 nucleotides by the cytoplasmic enzyme, Dicer. Following
processing, the miRNAs are incorporated into the RNA-induced
silencing complex (RISC) that mediates miRNA binding to the
3′ untranslated regions (3′UTR) of targeted messenger RNA
(mRNA). This binding negatively regulates gene expression by
translation inhibition, mRNA degradation or a combination of
both (Chamorro-Jorganes et al., 2013; Araldi et al., 2015). In
order to repress transcription, a crucial sequence of miRNA
located in position 2–8 (i.e., seed sequence) must be almost
perfectly complimentary to regions at the 3′UTR of the targeted
genes. Since, computational analysis indicates that 60% of
protein-coding genes harbor miRNA targets sites in their
3′UTR (Chen and Wang, 2013; Fu et al., 2013a; Yan et al.,
2013), it is likely that a single miRNA could modulate the
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TABLE 1 | Summary of studies of exosomes and microparticles in preeclampsia.
Extracellular vesicle
population
Subcellular origin Size, nm Alteration in preeclampsia References
Exosomes Endocytic pathway 40–120 Syncytin-2 lower in placental exosomes Vargas et al., 2014
63 proteins uniquely present in CTB-binding vesicles, and 80 in AV-binding
vesicles in preeclamptic samples. No description of main biological
pathways
Tan et al., 2014
Total exosomes concentration and placenta-derived exosomes were
elevated in plasma at first trimester of pregnancy (i.e., 11–14 weeks) in
women who develop PE later in pregnancy
Salomon et al., 2014b
29 proteins associated with multiple biological functions including
complement and coagulation cascade were differentially expressed in
umbilical blood exosomes
Jia et al., 2015
Exosomes positive for AQP2 were isolated from urine obtained from
patients with PE
Nielsen et al., 2015
Microvesicles or
shedding vesicles
Plasma membrane 50–1000 Uncharecterized microvesicles higher in plasma Dragovic et al., 2013
Elevated tissue factor within STBM Gardiner et al., 2011
Elevated STBM in early and late onset preeclampsia Chen et al., 2012
Elevated levels of DNA-associated placental microparticles Orozco et al., 2009
Alteration in lipids including higher PPTS and lower PPA, PPDG, and GM3. Baig et al., 2013
Proteomic analysis of STBM. Major biological functions altered: cell death
and survival, cellular assembly and organization, immune response, lipid
metabolism, and carbohydrate metabolism
Baig et al., 2014
PPTS, Phosphatidylserine; PPA, phosphatidic acid; PPDG, phosphatidylglycerol; GM3 ganglioside mannoside 3; STBM, syncytiotrophoblast microvesicles; CTB, Cholera toxin B chain;
AV, Annexin V; AQP2, Aquaporin-2.
expression of hundreds of genes (Chamorro-Jorganes et al.,
2013; Chen and Wang, 2013; Fu et al., 2013a; Yan et al.,
2013; Araldi et al., 2015). The complexity of these regulatory
mechanisms is even greater when we consider that miRNA
formation includes formation of thermodynamically less stable
strands (miRNA*), splicing variants, and there is evidence of
redundant expression in several genes. Also opposing actions
are determined by the targeted cells and their environment (i.e.,
hypoxia, normoxia, or oxidative stress). There is also cell and
tissue specific expression among other regulatory mechanisms
(Nishiguchi et al., 2015). Taking all of this into account, it
is not surprising that the study of miRNA is one of the
hottest topics in the studies of the cell biology of normal and
pathological conditions, including preeclampsia. In the latter,
there are at least a dozen preeclampsia-associated differentially
expressed miRNAs (Chen and Wang, 2013), most of them
relevant to impaired trophoblast invasion, that have been used as
biomarkers (see Table 1). However, we would like to emphasize
that few of these studies are related to the study of endothelial
function.
EXOSOMES, microRNA, AND
ENDOTHELIAL REGULATION: FOCUS ON
ANGIOGENESIS
Exosomes as a mechanism of intercellular communication
influence many endothelial functions, including vascular tone,
interaction between endothelial cells, smooth muscle cells
and pericytes, and angiogenesis. Also, a number of studies
have demonstrated a correlation between the number of
circulating (CD31+ CD41−) microvesicles and endothelial
dysfunction in coronary artery disease, type 2 diabetes mellitus,
hypertension, atherosclerosis, or cancer. miRNAs in exosomes
have a potential beneficial effects and may be involved in the
pathogenesis of cardiovascular diseases. There are numerous
reports demonstrating the effect of exosomes on endothelial
function. In this manuscript we will summarize such reports of
exosomes, miRNAs, and angiogenesis but interested readers may
find additional relevant information in other excellent reviews
(Chistiakov et al., 2015; Das and Halushka, 2015; Lawson et al.,
2016).
Halkein et al. (2013) studied peripartum cardiomyopathy
(PPCM) a life-threatening pregnancy-associated heart
dysfunction in previously healthy women. They found that
the 16-kDa N-terminal prolactin fragment, a peptide linked
with occurrence with PPCM, stimulated the release of miR-
146a-loaded exosomes from endothelial cells. Their target
cells were cardiomyocytes, which after incorporation of these
“mir-146a-loaded exosomes” decreased the expression of genes
including Erbb4, Notch 1, and Irak1 and down regulating
metabolic activity of cardiomyocytes. Further in vitro and
in vivo experiments, confirmed the involvement of miR-146a
in the PPCM. miRNAs contend in exosomes which target are
endothelial cells may down or up regulated angiogenesis process.
In the following section we present relevant studies illustrating
exosomal miRNAs that target endothelial cells and in particular
affect angiogenesis (see Table 2).
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TABLE 2 | miRNAs incorporated into exosomes that targeted endothelial cells modulating angiogenesis.
miRNA miRNA source Recipient cell Target gene References
miR-21 Human lung cancer HBEC VEGF Liu et al., 2016
miR-17, miR-20a, miR023a, miR-23b, miR-30b,
miR-30c, miR-126-3p, miR-132
Mice cardiomyocytes HUVEC Multiple target gene Garcia et al., 2015
miR-23, miR-320b MCF7 EA.hy926 PLAU, AMOTL1, NRP1, ETS2 Hannafon et al., 2015
miR-126 HUVEC HUVEC SPRED1, VECAM1, RGS16, CXCL12 Zernecke et al., 2009
miR-132 CPC HUVEC RasGAp-p120 Barile et al., 2014
miR-135b HR-MM HUVEC FIH-1 Umezu et al., 2014
miR-143 PASMC PAEC Deng et al., 2015
miR-150 THP-1 HMEC-1 c-Myb Zhang et al., 2010
miR-320 Cardiomyocytes CEC IGF1, HSP20, Ets2 Wang X. et al., 2014
miR142-3p, miR-223-3p BMDM iECL Multiple miRNAs Squadrito et al., 2014
HBEC, Human bronchial epithelial cells; HUVEC, human umbilical endothelial cells; CPC, cardiac progenitor cells; CEC, cardiac endothelial cells; PASMC, Pulmonary artery smooth
muscle cells; PAEC, pulmonary aortic endothelial cells; HR-MM, hypoxia resistant myelomas cell lines (RPMI8226); BMDM, Bone marrow derived macrophages; iECL, immortalized
endothelial-like cells from the hearth of Dicerfl/fl mice.
miR-21
miR-21 is up regulated in many diseases, in particular cancer, in
association with regulation of cell proliferation and apoptosis.
The gene for miR-21 is located on chromosome 17q23.2,
immediately downstream of the vacuole membrane protein 1
(VMP1) gene. miR-21 is increased in patient who are in high
risk of developing lung cancer duo to a smoking habit (Liu et al.,
2016). A human bronchial cell lines exposed to smoke extract
increase the synthesis and release of miR-21. When exosomes-
containing miR-21 isolated from those cells are transferred
to endothelial cells they stimulate angiogenesis. Also, when
transferred to bronchial cells they increase VEGF in dose-related
manner. Exosomes labeled with green fluorescent dye increase
incorporation of exosomes-containing miR-21 into endothelial
cells. Based upon these observations the authors concluded that
exosomes-containing miR-21 may increase tumor angiogenesis
in lung cancer.
Exosomes harvested from breast cancer cells exposed to
docosahexaenoic acid (DHA) exhibited high levels of 22 miRNAs
(see Table 2). miR-21, miR-23b, miR-27b, and miR-320, miRNAs
that have known activity in targeting endothelial cells to suppress
angiogenesis. Mechanism for anti-angiogenic effect of the last
miRNAs was confirmed using either exosomes released by a
DHA-treated breast cancer cell line (MCF7 cells) or transfected
endothelial cell (i.e., EA.hy926 cells). Each of these miRNAs,
upregulated let-7a, miR-21, miR-23b, miR-27b, and miR-320b in
the endothelial cells. They also reduced tube formation capacity
and the expression of pro-angiogenic target genes (Hannafon
et al., 2015; see Table 3).
In placentas from preeclamptic pregnancies, down regulation
(Choi et al., 2013), or up regulation of miR-21 in placentas
with abnormal Doppler analysis has been reported, where there
were no changes with preeclamptic women with normal Doppler
(Cindrova-Davies et al., 2013). Although, no specific target was
analyzed in this last study, bioinformatics reveals potential target
for miR-21 such as nuclear factor I/B (NFIB) and ras homolog
family member B (RHOB) genes (Choi et al., 2013).
Others have studied cardiomyocytes-endothelial crosstalk by
miRNAs containing in exosomes. Garcia et al. (2015) studying
cardiomyocytes isolated from neonatal mice and exposed
to low glucose medium (starvation conditions), found that
amongst the 380 miRNA tested, 30 miRNA were expressed
in starvation, 13 miRNA in control, and only eight miRNA
in both conditions. in these were significantly increased with
starvation. The main groups of genes were associated with
cell proliferation, cell-cycle, and protein transport. Target genes
included MAPK, Wnt, p53, VEGF, Notch signaling pathway,
endocytosis, among others. Interestingly for our current analysis,
when exosomes from cardiomyocytes were transferred to
endothelial cells, they were incorporated, this was associated
with up-regulation of pro-angiogenic related genes such as
angiopoietins type 1 (ANGPT) and angiopoietin-like protein
4 (ANGPTL4). Accordingly, cardiomyocytes-derived exosomes
increase endothelial proliferation and tube formation capacity.
The study suggests that miRNA within exosomes can modulate
cell–cell communication. However, which miRNA might direct
these effects upon pro-angiogenic endothelial capacity was not
specified. In the heart, there is also cross talk between the
cardiac progenitor cell (CPC) population and endothelial cells.
An example of this is found in the work by Barile et al. (2014) who
characterized exosomes released by CPC, which content include
several angiogenic related miRNA, miR-210, miR-132, and miR-
1461-3p. A cardioprotective role of miR-210 and miR-132 was
further characterized, with evidence that both induce apoptotic
protection of a cardiomyocytic cell line (HL-1). In addition, miR-
132 promoted the formation of endothelial tubes, confirming the
pro-angiogenic role of miRNAs packaged into exosomes. This
has been reviewed by Cervio et al. (2015).
Other examples include pulmonary artery smoothmuscle cells
(PASMCs) cross talk with endothelial cells. Deng et al. (2015)
observed high abundance of miR-143-3p in PASMC-derived
exosomes. Similar to the previous description, a paracrine
pro-angiogenic effect of miR-143-3p-enriched exosomes from
PASMC transferred to pulmonary arterial endothelial cells. No
specific target for miR-143-3p was identified in this study.
Interestingly, a deficiency of miR-143 prevented the development
of pulmonary hypertension in an in vivo experiment (Deng et al.,
2015).
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TABLE 3 | Summary of studies of miRNAs in preeclampsia.
miRNAs Levels Target genes References
PLACENTA
miR-1301, miR-223, and miR-224 ↓ Leptin gene Weedon-Fekjaer et al.,
2014
miR-92b, miR-197, miR-342-3p, miR-296-5p, miR-26b, miR-25,
miR-296-3p, miR-26a, miR-198, miR-202, miR-191, miR-95, and
miR-204
↑ Multiple targets in several signaling pathways,
adherent junction, focal adhesion, and regulation of
the actin cytoskeleton
Choi et al., 2013
miR-21 and miR-223 ↓
hsa-miR-v5 ↓ Not reported Lazar et al., 2012
miR-17, -20a, and -20b ↑ EPHB4 and Eph-B2 Wang W. et al., 2012
miR-20a, miR-210, miR-451, miR-518c, and miR-526b* ↑ HSD17B1 Ishibashi et al., 2012
PLACENTA AND TROPHOBLAST
miR-125b-1-3p ↑ S1PR1 Li Q. et al., 2014†
miR-210 ↑ KCMF1 Luo et al., 2014†
miR-210 ↑ Iron sulfur cluster Muralimanoharan et al.,
2012
miR-210 ↑ ERK signaling Anton et al., 2013†α
‘miR-18a, miR-19b1, and miR-92a1 ↓ Smad2 (miR-18a) Xu et al., 2014
miR-210 ↑
miR-155 ↑ eNOS Li X. et al., 2014†
pri-miR-34a ↑ SERPINA3 Doridot et al., 2014
miR-101 ↓ ERp44 Zou et al., 2014‡
miR-195 ↓ ActRIIA Bai et al., 2012
miR-106a and −19b ↑ hCYP19A gene and hGCM1 Kumar et al., 2013†
TROPHOBLAST CELL LINES
miR-376c ↓ ALK5 and ALK7 Fu et al., 2013b
miR-20a ↑ FOXA1 Wang Y. et al., 2014
miR-29b ↑ MCL1, MMP2, VEGFA and ITGB1 Li H. et al., 2013
STEM CELLS
microRNA-494 ↑ CDK6, CCND1, VEGF Chen et al., 2015
miR-136, miR-495, miR-16, miR-29b and miR-494 ↑ Multiple targets involved in angiogenesis (VEGF),
inflammation, differentiation of MSC
Zhao et al., 2014
miR-126 ↓ PIK3R2 Yan et al., 2013
miR-16 ↑ CCNE1, VEGF Wang Y. et al., 2012
PLASMA AND WHOLE BLOOD
miR-1233 ↑ Not reported Ura et al., 2014
C19MC microRNAs (miR-516-5p, miR-517*, miR-520a*,
miR-520h, miR-525, and miR-526a)
↑ Not reported Hromadnikova et al.,
2013
miR-141, miR-144, miR-221, and miR-29a ↑ Not reported Li et al., 2013
miR-516-5p, miR-517*, miR-518b, miR-520a*, miR-520h,
miR-525, and miR-526a
↑ Not reported Hromadnikova et al.,
2012
miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p,
and miR-574-5p
↑ Not reported Wu et al., 2012
Data since 2012. CDK6, Cyclin-dependent kinase 6; CCND1, Cyclin D1; VEGF, Vascular endothelial growth factor; S1PR1, Sphingosine-1-phosphate receptor 1; FOXA1, Forkhead
box protein A1; KCMF1, Potassium channel modulatory factor 1; eNOS, endothelial nitric oxide synthase; ERp44, Endoplasmic reticulum protein 44; Smad2, SMAD family member 2;
SERPINA3, Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin); member 3, ERK, Extracellular-signal-regulated kinases; hCYP19A, Human aromatese gene; GCM1,
transcription factor glial cells missing 1; PIK3R2, phosphoinositide-3-kinase regulatory subunit 2; ALK5 and ALK7, Activin receptor-like kinase 5 and ALK7; CCNE1, Cyclin E1; ActRIIA,
Type II receptor for Activin A and Nodal; MCL1, myeloid cell leukemia sequence 1; MMP2, matrix metallproteinase 2; ITGB1, integrin β1; EPHB4, EPH receptor B4; EphB2, Ephrin-B2;
HSD17B1, hydroxysteroid (17-β) dehydrogenase 1;
†
, Report reduce trophoblast invasion;
‡
, Enhance trophoblast apoptosis; α, Predictive role for preeclampsia; *, From the opposite
arm of the precursor.
ANGIOGENESIS AS A TARGET OF miRNA
IN PREECLAMPSIA
The relevance of miRNA to endothelial function is demonstrated
by knockdown of Dicer in endothelial cells, which inhibits
proliferation and tube formation in vitro (Kuehbacher et al.,
2007). Endothelium-specific Dicer knockout mice have impaired
blood vessel development (Suarez et al., 2007). Furthermore
hypoxia, a phenomenon present in preeclampsia, down-regulates
Dicer function, and expression in endothelial cells (Ho et al.,
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2012). An increasing number of publications have investigated
endothelial-related miRNAs and their potential importance to
preeclampsia. Most of them, however, have focused on the
placenta or maternal blood (see Table 3). In the next section we
describe miRNAs that target endothelial cells. There is, however,
no information as to whether these miRNAs are present in
exosomes.
miR-126
miR-126 is encoded by intron 7 of the epidermal growth
factor- like domain 7 (egfl7) gene and highly expressed in
human endothelial cells (Bai et al., 2014). The precursor pre-
miR-126 gives rise to two mature strands, miR-126-3p and
miR126-5p. The expression, and target of that miR-126s may
be different in endothelial cells (Fish et al., 2008; Wei et al.,
2013; Poissonnier et al., 2014). In miR126−/− mice at least
513 genes (including VEGF, EGFL7, CD31, RGS3, v-CRK) were
up regulated in injured carotid arteries isolated from those
animals (Schober et al., 2014). Among targets genes, miR-
126 negatively regulates sprout-related protein (SPRED1) and
phosphoinositol-3 kinase regulatory subunit 2 (PIK3R2/p85-B),
which is involved in VEGF pathway (Nishiguchi et al., 2015).
Deletion of the gene encoding pre-miR-126 affects vascular
integrity and angiogenesis during development without causing
overt abnormalities after birth (Fish et al., 2008). However,
ischemic neovascularization is severely impaired in miR126−/−
mice (Wang et al., 2008). In preeclampsia, Yang and colleagues
reported elevated miR-126 (and mir-126∗ among other 20
miRNAs) in plasma and placenta (Yang et al., 2015), whereas
Yan and colleagues reported decreased miR-126 expression
in both umbilical endothelial progenitor cells and placentas
from preeclamptic pregnancies (Yan et al., 2013). This latter
study found that miR-126 down regulated the expression
of the anti-angiogenic gene PIK3R2 that is involved in the
negative regulation of PI3K-Akt signaling pathways. Also, miR-
126 manifested a pro-vasculogenic capacity, enhancing the
proliferation, migration, and angiogenic capacity of umbilical
endothelial progenitor cells (ECP). The increased angiogenic
capacity was confirmed in pregnant rats in which miR-126
increased vascular sprouting, as well as placenta and fetal weights
(Yan et al., 2013). These findings suggest that the reduction in
miR-126 present in preeclampsia might impair placental vascular
development. In other studies of reduced expression of miR-
126 in preeclampsia placentas, there was a correlation of mir-
126 levels with placental expression of VEGF (Hong et al.,
2014). Consistent with this, in gain-loss assays miR-126 regulated
VEGF expression in BeWo cells, confirming that VEGF is a
target gene of the miR126. Despite this analysis, comparative
expression of miR-126 and its target genes in maternal and fetal
circulation during preeclamptic pregnancies has not yet been
performed.
miR17-92 Cluster
miR17-92 cluster is one of the best-characterized polysistronic
miRNAs. It is located in intron 3 of the C13orf25 gene
(chromosome 13q31.3). The cluster contains six miRNAs
including miR17, miR-18, miR-19a, miR-19b-1, miR-20a, and
miR-92a-1. These are processed from a common precursor
transcript. Based on their seed sequences, they are grouped
into four families: the miR-17 family (miR-17 and miR-20a),
the miR-18 family, the miR-19 family, and the miR-92 family.
Based upon sequence analysis miR-17, miR20a, and miR-
20b possess overlapping function, targeting similar sets of
genes, including hypoxia inducible factor 1 alpha (HIF1A),
interleukin 8 (IL-8), tissue inhibitor of metalloproteinases
2, matrix metallopeptidase 2, VEGFA, ephring-B2, and Eph
receptor B4 (EPHB4; Wang W. et al., 2012; Chen and Wang,
2013). In endothelial cells, overexpression of miR17-92 cluster
was linked to down regulation of anti-angiogenic proteins
such as connective tissue growth factor (CTGF), and Tsp-
1 (targets of miR-18 and miR-19), and tissue inhibitor of
metalloproteinase 1 (TIMP1). This cluster, in particular miR-
17 or miR-19, also negatively regulates the expression of pro-
angiogenic Janus kinase 1 (JAK1), or cyclin D1 (CCND1; see
details in Chamorro-Jorganes et al., 2013). Other target genes
down regulated by this cluster, in particular by miR-92a, are
sphingosine-1-phosphate receptor 1 (S1P1), mitogen-activated
kinase kinase 4 (MKK4), and eNOS (Bonauer et al., 2009).
Wang W. et al. (2012) found that miR-17, miR-20a, and miR-
20 b were significantly increased in placentas from preeclamptic
compared with control placentas. With in silico analysis, these
authors describe several angiogenesis-related genes, including
HIF-1 α-subunit (HIF1A), IL-8, EPHB4, tissue inhibitor of
metalloproteinase 2 (TIMP2), VEGF, ephrin-B2 (EFNB2), and
matrix metallopeptidase 2 (MMP2) as potential targets of miR-
17, miR-20a, and miR-20b. In vitro experiments confirm that
miR-20b overexpression reduce EPHB4; whereas co-transfection
of miR-20b antagomir to inhibit miR-20b expression increased
the expression of HIF1A, MMP2, and EFNB2 by about 60–70%
in human umbilical vein endothelial cells (HUVEC). Inhibition
of miR-20b also reduced VEGFA expression. Altogether these
results suggest that decreased expression of cluster miR17-92
might also be related with endothelial dysfunction present in
preeclampsia.
miR-210
mir-210 is a hypoxia-induced miRNAs well-studied in cancer.
It is located in the intronic sequence of mRNA transcript
AK123483 that itself is hypoxia-inducible. Multiple groups have
found that miR-210 is specifically induced by HIF-1α, and it is
considered one of the hallmarks of hypoxic induced response in
several cell types including endothelial cells (Chan and Loscalzo,
2010). To date, more than 50 genes have been identified as
direct targets of miR-210. These genes are involved in cells
processes such as metabolism (mitochondrial proteins, including
iron sulfur cluster assembly proteins ISCU1 and ISCU2), cell
survival, proliferation and angiogenesis (i.e., fibroblast growth
factor receptor, FGFR; ephrin-A3, EFNA3; c-MYC antagonist,
MNT; homeobox-A9, HOXA9, etc.; see details in Chan and
Loscalzo, 2010). In preeclampsia, miR-210 is one of the miRNAs
that consistently (Liu et al., 2012), exhibits high expression in
placenta (Pineles et al., 2007; Enquobahrie et al., 2011; Lee
et al., 2011; Muralimanoharan et al., 2012; Luo et al., 2014), or
increased concentration in maternal whole blood (Gunel et al.,
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2011; Anton et al., 2013; Murphy et al., 2015) especially in
severe preeclampsia (Zhu et al., 2009; Zhang Y. et al., 2012; Xu
et al., 2014). Despite this, few studies have investigated miR-
210 targeted genes that include potassium channel modulatory
factor 1 (KCMF1; Luo et al., 2014), mitochondrial complex
III (Muralimanoharan et al., 2012), hydroxysteroid (17-β)
dehydrogenase 1 (HSD17B1; Ishibashi et al., 2012), ISCU (Lee
et al., 2011), EFNA3 and HOXA9 (Zhang Y. et al., 2012).
All of these are associated with reduced trophoblast invasion.
Interestingly, no studies have yet been published of the regulation
of miR210 in endothelial cells from thematernal or feto-placental
circulation.
CONCLUDING REMARK AND
HIGHLIGHTED POINTS
Endothelial dysfunction in both the maternal and feto-placental
circulation is a hallmark of preeclamptic pregnancy. This
dysfunction includes down-regulation of genes involved in
regulation of vascular tone, membrane transporter function,
endothelial survival or proliferation, angiogenesis, and metabolic
pathways. The question of how these alterations are generated
in the preeclamptic pregnancy remains unanswered. There are
numerous reports of increased circulating concentration of
endothelial-released proteins related to endothelial dysfunction.
These are proposed to be released from the placenta. In this
scenario, the release of extracellular vesicles from the placenta,
has attracted great attention. It is proposed that endothelial
function is modified by lipids in the wall of the vesicle but
perhaps more importantly by the cargo within the vesicle.
Indeed, miRNAs within these vesicles (in particular exosomes)
and their target genes may explain the extensive modification
of endothelial-protein expression present in preeclampsia.
Characterization of the expression of these regulators and
their target genes is of great potential importance not only
in preeclampsia, but also may indicate artificially constructed
cargo exosomes that with appropriate miRNA could constitute
a new area of genetic treatment. They also may provide potential
biomarkers but more importantly understanding the regulation
and role of these molecules should lead to a better understanding
of these processes.
The ability of biomarkers to predict women at risk to develop
preeclampsia has been extensively studied. However, despite
enormous effort, thus far no markers, including exosomes and
microRNAs, are effective predictors. This fact is not only due
to limitations (i.e., big data, expensive, biological meaning,
among others), but also due to the fact that preeclampsia is
a syndrome not a discrete disease (Myatt and Roberts, 2015).
Currently there are global initiatives searching to characterize
subtypes of the disease in different populations, which should
facilitate validation of biomarkers. To accomplish this we must
consider the epidemiology of preeclampsia. In in low andmiddle-
income countries where there are limitations on resources for
expensive technologies, the prevalence andmortality greater than
in high-income countries. Thus the clinical application for using
exosomes and miRNAs is a huge challenge.
Nevertheless, study of exosomes and its content including
miRNAs will allow translation of the language of the
remarkable mother-placenta-fetus communication in normal
and pathological pregnancies. Exosomes and miRNAs constitute
a cell–cell communication system, and we are beginning to
understand the relevant mechanisms. We have focused on
endothelial cells, and more specifically on angiogenic processes.
It is possible that exosomes and miRNAs might have quite
different effects depending on the micro-environment. As an
example, exosomes released by tumors or with hypoxic stress
increase angiogenesis, while in preeclampsia, EVs including
exosomes may lead to endothelial dysfunction. Diversity
of response is characteristic of EVs. As described in this
manuscript, the synthesis of exosomes is modified by hypoxia,
glucose content, and pro-oxidative/anti-oxidative balance,
among others. This variability is not only in the number of
exosomes but also membrane and vesicle content. Recipient
cells may also modulate incorporation of these cell particles via
TLRs. Once inside recipient cells, cargo is released and message
code is read. However, this also will depend upon the micro-
environment of the recipient cells. Although, there has been
progress in the understanding these processes there is limited
information available about pregnancy. Future research should
be directed to better understand the role of exosomes and their
cargo in mother-placenta-fetal communication. In the field of
preeclampsia, there is little information about miRNAs included
in exosomes or EVs, that we know have the capacity to modulate
gene targets and generate endothelial dysfunction and/or impair
angiogenesis. We have summarized information on the actions
of miRNA-21, miRNA-126, miRNA-132, miRNA-143, miRNA-
210, miRNA-320, and other miRNAs with potential significance
to endothelial dysfunction during preeclampsia due to their
affect upon angiogenic processes. However, we acknowledge
that this constitute a substantial limitation since compared to
extensive information on this this topic in the cardiovascular
field little is known about preeclampsia. Endothelial dysfunction
is a hallmark of preeclampsia and we encourage future research
in this area.
At the moment only a few reports have the potential role
of endothelial regulator miRNA in preeclampsia. In the few
reports available progress has been limited by variability of the
analysis including particle size analyzed. Differences in EVs
content, and the large number of targets genes including nearly
all of those modulating metabolic function in the endothelial
cells that might be impaired support the importance of these
interactions. Fruitful targets for investigation are underling
mechanism determining miRNA release from placenta and their
impact on endothelial function.
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